Hyderabad-headquartered Bharat Biotech International Ltd (BBIL) has reportedly submitted all documents required for Emergency Use Listing or EUL of the covid-19 vaccine Covaxin to the World Health Organization (WHO) as of July 9.
The biotech major has also said that the review process has now started. It expects to obtain EUL from WHO soon. WHO’s Chief Scientist Soumya Swaminathan had recently said that it may take a decision if it will include Covaxin in the EUL within four to six weeks. She had also said that WHO was reviewing Covaxin as its producer BBIL submits all information on WHO portal.
According to WHO guidelines, EUL is a procedure for process streamlining, wherein approval and use for novel products can be granted during a pandemic or other public health emergencies.
Until now, the global health body has granted approved for Covid-19 vaccines of Astrazeneca-SK Bio/Serum Institute of India, AstraZeneca E, Moderna, Pfizer/BioNTech, Janssen, and Sinopharm for EUL.